



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/541,749	03/03/2006	Lukas C. Amler	D0304 NP	9819
23914	7590	04/02/2008	EXAMINER	
LOUIS J. WILLE			GUSSOV, ANNE	
BRISTOL-MYERS SQUIBB COMPANY			ART UNIT	PAPER NUMBER
PATENT DEPARTMENT			1643	
P O BOX 4000				
PRINCETON, NJ 08543-4000				
NOTIFICATION DATE	DELIVERY MODE			
04/02/2008	ELECTRONIC			

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

uspatents@BMS.COM
patents@bms.com
cileen.inmordino@bms.com

Office Action Summary	Application No. 10/541,749	Applicant(s) AMLER ET AL.
	Examiner ANNE M. GUSSOW	Art Unit 1643

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If no period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 07 February 2008.
 2a) This action is FINAL. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1,3 and 4 is/are pending in the application.
 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
 5) Claim(s) _____ is/are allowed.
 6) Claim(s) 1,3 and 4 is/are rejected.
 7) Claim(s) _____ is/are objected to.
 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on 07 July 2005 is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
 3) Information Disclosure Statement(s) (PTO/1449)
 Paper No(s)/Mail Date 7/7/05, 2/7/08

4) Interview Summary (PTO-413)
 Paper No(s)/Mail Date _____
 5) Notice of Informal Patent Application
 6) Other: _____

DETAILED ACTION

1. Applicant's election without traverse of the biomarker mucin 2 in the reply filed on February 7, 2008 is acknowledged.

2. Claim 2 has been cancelled.
Claims 1, 3, and 4 have been amended.

3. Claims 1, 3 and 4 are under examination.

Information Disclosure Statement

4. The information disclosure statements (IDS) submitted on July 7, 2007 and February 7, 2008 have been fully considered by the examiner and an initialed copy of the IDS is included with the mailing of this office action.

Claim Rejections - 35 USC § 112

5. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

6. Claims 1, 3, and 4 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for identifying a mammal that will respond therapeutically to a method of treating cancer comprising administering an EGFR

Art Unit: 1643

modulator by measuring the mRNA level of the biomarker mucin 2, does not reasonably provide enablement for measuring the protein level of the biomarker mucin 2. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make or use the invention commensurate in scope with these claims.

Factors to be considered in determining whether a disclosure meets the enablement requirement of 35 USC 112, first paragraph, have been described by the court in *In re Wands*, 8 USPQ2d 1400 (CA FC 1988).

Wands states on page 1404,

"Factors to be considered in determining whether a disclosure would require undue experimentation have been summarized by the board in *Ex parte Forman*. They include (1) the quantity of experimentation necessary, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art, and (8) the breadth of the claims."

The specification discloses detection of mucin 2 expression by microarray and RT-PCR assays in cancer cell lines. The specification does not disclose detection of mucin 2 protein.

Those of skill in the art, recognize that expression of mRNA, specific for a tissue type, does not dictate nor predict the translation of such mRNA into a polypeptide. For example, Alberts et al. (*Molecular Biology of the Cell*, 3rd edition, 1994, page 465) teach that translation of ferritin mRNA into ferritin polypeptide is blocked during periods of iron starvation. Likewise, if excess iron is available, the transferrin receptor mRNA is degraded and no transferrin receptor polypeptide is translated. Many other proteins are regulated at the translational level rather than the transcriptional level. For instance,

Shantz and Pegg (International Journal of Biochemistry and Cell Biology, 1999. Vol. 31, pages 107-122) teach that ornithine decarboxylase is highly regulated in the cell at the level of translation and that translation of ornithine decarboxylase mRNA is dependent on the secondary structure of the mRNA and the availability of eIF-4E, which mediates translation initiation. McClean and Hill (European Journal of Cancer, 1993. Vol. 29A, pages 2243-2248) teach that p-glycoprotein can be overexpressed in CHO cells following exposure to radiation, without any concomitant overexpression of the p-glycoprotein mRNA. In addition, Fu et al (EMBO Journal, 1996. Vol. 15, pages 4392-4401) teach that levels of p53 protein expression do not correlate with levels of p53 mRNA levels in blast cells taken from patients with acute myelogenous leukemia, said patients being without mutations in the p53 gene. Thus, predictability of protein translation is not necessarily contingent on mRNA expression due to the multitude of homeostatic factors affecting transcription and translation. Therefore, one of skill in the art would not be able to predict if mucin 2 mRNA is in fact translated into the mucin 2 polypeptide in the biological samples. Thus, predictability of protein translation is not necessarily contingent on its expression due to the multitude of homeostatic factors affecting transcription and translation.

Claim Rejections - 35 USC § 102

7. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

8. Claims 1, 3, and 4 are rejected under 35 U.S.C. 102(a) as being anticipated by Perrais, et al. (Journal of Biological Chemistry, 2002. Vol. 277, pages 32258-32267, as cited on the IDS).

The claims recite a method for identifying a mammal that will respond therapeutically to a method of treating cancer comprising administering an EGFR modulator, wherein the method comprises: (a) measuring in the mammal the level of a biomarker comprising mucin 2; (b) exposing the mammal to the EGFR modulator; (c) following the exposing of step (b), measuring in the mammal the level of the biomarker, wherein a difference in the level of the ~~at least one~~-biomarker measured in step (c) compared to the level of the biomarker measured in step (a) indicates that the mammal will respond therapeutically to said method of treating cancer, wherein the method is an in vitro method, and wherein the biomarker is measured in at least one mammalian biological sample from the mammal. A method for identifying a mammal that will respond therapeutically to a method of treating cancer comprising administering an EGFR modulator, wherein the method comprises: (a) exposing the mammal to the EGFR modulator; (b) following the exposing of step (a), measuring in the mammal the level of the a biomarker comprising mucin 2, wherein a difference in the level of the biomarker measured in step (b), compared to the level of the biomarker in a mammal that has not been exposed to said EGFR modulator, indicates that the mammal will respond therapeutically to said method of treating cancer.

Perrais, et al. teach treatment of lung cancer cell lines with epidermal growth factor (EGF) and detection of an increase in mucin 2 mRNA levels as a result of the EGF. EGF would be considered an EGFR modulator because EGF would bind to the EGFR (EGF receptor). Perrais, et al. teach comparison of the treated cells to non-treated cells. Perrais, et al. teach that the increase in mucin 2 expression is at the transcriptional level and that activation does not require de novo protein synthesis. Since Perrais, et al. teach each of the active steps of the method; measurement of mucin 2 levels, addition of an EGFR modulator, and comparison of the level of mucin 2 before and after treatment, all the limitations of the claims have been met.

Conclusion

9. No claims are allowed.

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ANNE M. GUSSOW whose telephone number is (571)272-6047. The examiner can normally be reached on Monday - Friday 8:30 am - 5 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Larry Helms can be reached on (571) 272-0832. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for

published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Anne M. Gussow

March 26, 2008

/Larry R. Helms/
Supervisory Patent Examiner, Art Unit 1643